A 16-week lifestyle program for people with multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, waitlist-controlled study enrolls adults with multiple myeloma to participate in a 16-week lifestyle program focused on diet and physical activity. Participants undergo in-person assessments for physical function, body composition, and a blood draw, with surveys completed remotely 3–4 times during the study. After baseline data collection, participants are randomized to start the lifestyle program immediately or after a 16-week waitlist, ensuring all participants eventually receive the intervention. The study evaluates changes in physical function, QoL, and biological aging biomarkers to determine potential benefits for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult (≥ 18 years)
2. Diagnosed with MM at least one year prior to study enrollment
3. 100 days post transplant (if applicable)
4. Has access to a smart phone or device with internet access
5. Be deemed "clinically stable" by their physician guided by the following:

   1. not expected to receive therapies beyond maintenance (for 100 days)
   2. no new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND
   3. stable performance status (ECOG 0-2) assessed in the last 3 months
6. No reports of severe pain \> Grade 3 \[defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)\].
7. Able to participate in PA and strength training per clinician approval and confirmed by participant
8. Able to understand and willing to sign a written informed consent document
9. English proficient for reading and writing

Exclusion Criteria:

1. Coexistent amyloidosis, POEMS syndrome will not be approached
2. Fully adherent to the ACS nutrition and physical activity guidelines
3. If participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period
4. On another interventional clinical trial that precludes co-enrollment
5. Psychiatric or other clinical conditions that preclude study compliance
6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician

Where it's running

• Loyola University Chicago
  Maywood, Illinois, United States Recruiting
• Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Melinda Stolley, PhD — Medical College of Wisconsin
• Study coordinator: Melinda Stolley, PhD
• Email: mstolley@mcw.edu
• Phone: (312)735-6044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive changes after BCMA CAR-T in multiple myeloma

  This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT07740317

• GPRC5D-targeted PET/CT imaging in plasma cell disorders

  This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.

  Recruiting Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07660939

• Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy

  This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.

  Recruiting at 2 sites Wuerzburg University Hospital · Augsburg, Bavaria and 5 other locations · NCT07649681

• Personalising Myeloma Treatment Based on Initial Response and Fitness

  This trial tests whether adjusting treatment after six months of the standard DRd therapy, based on a patient’s response and fitness, can improve outcomes for older, transplant-ineligible patients with myeloma.

  Recruiting Phase 3 University of Leeds · Bristol and 4 other locations · NCT07649525

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment

  This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07585760

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.